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pelvis from imaging. There were no significant differences in 
bladder dose. The magnitude of benefit of daily imaging for a 
patient could not be predicted by characteristics on planning 
CT scan. 
 
Conclusions: Daily online CBCT verification imaging improves 
CTV coverage and reduces dose to rectum during IGRT for 
prostate cancer.  
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Purpose/Objective: This study aimed to investigate the 
impact of increasing radiation delivery time on the outcome 
of hypofractionated radiation therapy for prostate cancer. 
Intrafraction repair is seldom discussed in relation to external 
beam radiation therapy as most fractional doses are 
delivered in the course of a few minutes and the beam-on 
time is not very much different from the time to deliver all 
individual fields. Advanced techniques aimed at delivering 
high fractional dose, employing multiple fields, scanning the 
target volume or requiring multiple imaging sessions may 
however take considerably longer, increasing the importance 
of intrafraction repair. 
Materials and Methods: Mono-exponential and bi-exponential 
repair models have been used in prostate patients to study 
the loss of biologically effective dose for several clinically-
relevant irradiation times between 5 and 60 minutes. These 
were then converted into loss of biochemical control at 5 
years using clinically-relevant dose response curves derived 
from 10688 prostate patients treated with conventional 
fractionation. The theoretical predictions were subsequently 
compared with clinical results from 14 newly reported studies 
totalling 4363 patients undergoing conventionally-
fractionated and hypofractionated prostate radiotherapy. 
Results: For low-risk patients the equivalent doses delivered 
were quite high and consequently the reported results were 
very good and in agreement with theoretical predictions. For 
intermediate- and high-risk patients however, the results 
from hypofractionated schedules delivered with time-
consuming techniques appear to be compatible with 
predictions accounting for intrafraction repair taking place 
during longer irradiations, while results from moderately 
hypofractionated or conventionally-fractionated schedules 
are in agreement with short irradiation times. Treatment 
sessions lasting more than about 20 minutes could lead to 
significant loss of biochemical control even when relatively 
slow repair is relevant for prostate tumours. Large effect 
losses could therefore be expected from extremely 
hypofractionated schedules with long irradiation sessions as 
might be the case of scanned beams and/or with multiple 
intrafraction imaging sessions to check the positioning of the 
patient. The loss of effect might also be reflected into an 
apparent reduced sensitivity to fractionation for the tumours. 
Conclusions: Intrafraction repair plays an important role for 
prostate radiation therapy and may lead to loss of biological 
effect in the case of extremely hypofractionated techniques 
requiring increased irradiation times Neglecting intrafraction 
could also interfere with the derivation of the fractionation 
sensitivity for prostate tumours.  
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Purpose/Objective: To test the hypothesis that implantation 
of a hydrogel rectum spacer in patients with prostate cancer 
undergoing intensity modulated radiation therapy (IMRT) 
reduces predicted probabilities for grade 2-3 (Gr2-3) acute 
and late rectal toxicities. 
Materials and Methods: In 26 patients with localized prostate 
cancer (low-risk:8/26(31%); intermediate-risk: 11/26 (42%); 
high-risk: 7/26 (27%)), a hydrogel spacer (SpaceOAR®, 
Augmenix) was injected under transrectal ultrasound 
guidance in Denonvilliers’ space between the prostate and 
the rectal wall. IMRT treatment plans (78 Gy in 39 fractions) 
were designed based on CT scans acquired before (IMRT-pre) 
and after (IMRT-post) hydrogel injection. Published 
nomograms based on clinical risk factors (use of 
anticoagulantia, hormonal therapy, and anti-hypertensives, 
presence of diabetes, haemorrhoids, pre-EBRT abdominal 
surgery) and dose-volume histogram (DVH) parameters (V40Gy, 
V75Gy) were used to estimate predicted probabilities for Gr2-3 
acute gastro-intestinal (GI) toxicity1, Gr2-3 late rectal 
bleeding (LRB)2, and Gr2-3 fecal incontinence (FI)2 for IMRT-
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pre and IMRT-post plans. Normal tissue complication 
probabilities (NTCPs) for severe proctitis/necrosis/fistula 
were computed applying the Lyman-Kutcher-Burman model 
with Emami parameters (n = 0.02, m = 0.15, D50 = 80 Gy) on 
the rectum DVHs. A paired-sample one-sided Wilcoxon signed 
rank test was used to test for significant (p<0.01) 
differences. 
Results: Median implanted hydrogel volume was 10.6 cc 
[range: 8.3-20.4 cc]. Median V40Gy and V75Gy was 53.75% and 
3.96% for IMRT-pre, and 48.73% and 0.37% for IMRT-post, 
respectively. IMRT-post plans showed significant lower 
predicted Gr2-3 acute and late rectal toxicity rates relative 
to IMRT-pre plans: an absolute median decrease of 3% for 
Gr2-3 acute GI toxicity (p<0.001), a relative decrease of 50% 
for Gr2-3 LRB (p<0.0001) and a mean decrease of 1% for Gr 2-
3 FI (p<0.01). A median absolute reduction of 3.6% (>50% 
relative reduction) (p<0.00001) was predicted by the rectum 
NTCP model. 
Conclusions: In prostate cancer undergoing IMRT predicted 
Gr2-3 acute and late rectal toxicity rates decrease 
significantly by implantation of a hydrogel rectum spacer. We 
anticipate that the effect would be even larger in the high 
risk group. A follow-up study is mandatory to validate the 
predicted (decrease in) probabilities based on observed 
toxicity rates. 
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Purpose/Objective: The aim of this study was to evaluate 
the feasibility and safety of reirradiation using image-guided 
hypofractionated radiotherapy and real time tracking (4D 
Calypso® System) in patients (pts) with recurrence of 
prostate cancer after external beam radiotherapy (EBRT). 
Materials and Methods: Between May 2013 and August 2014, 
6 pts with local recurrence after EBRT were treated using 
VMAT (Volumetric Modulated Arc Therapya) and 4D localize 
and real time tracking Calypso® System. Houston-Phoenix 
definition (PSA nadir + 2 ng/mL) was used to define 
biochemical failure and all pts were assessed with endorectal 
MRI and choline PET/CT. Patients classification according to 
D’Amico Risk Group Class was the following: 2 pts high, 4 
intermediate and 1 low risk class. Mean time to recurrence 
was 56.4 months (range 19-96 months). All the pts had been 
treated with 3DCRT with a mean dose of 74.4 (72-76, median 
74). Total reirradiation dose was 25 Gy (5 fractions of 500 
cGy on alternate days). Simulation CT with specific 
preparation (empty rectum, filled bladder with catheter 
insertion) was performed after 5-7 days from Calypso® 
beacons implatation. Treatment planning was performed with 
Varian Eclypse v.8.6 in four pts and with v.10.6 in two; two 
pts were treated using X6 FFF (flattening filter free) photons. 
Mean CTV volume was 22.77cc (range 16.56-29.6 cc); PTV 
was obtained with a 3 mm isotropic expansion. Contouring of 
Organ At Risk (OAR) included urethra. Mean PTV dose 
coverage was 25.06 Gy, (range 24.7-25.4 Gy); maximum PTV 
allowed dose was 104% (urethra maximum dose allowed was 
102%). OAR dose constraints were obtained converting the 
RTOG conventional ones using alfa/beta ratio. Mean CI 
(conformity index) was 0.92 (range 0.89-1.05). Radiation 
Therapy Oncology Group/European Organization for Research 
and Treatment of Cancer criteria were used to assess toxicity 
of both treatments. 
Results: After a median follow-up of 14 months (range 2-17.6 
months), all pts were alive with no evidence of urinary or 
rectal toxicity. In four pts a biochemical response was 
observed; one pts, after an initial PSA reduction, showed a 
rising of the marker due to metastatic disease. One patient is 
not yet evaluable. 
Conclusions: Salvage hypofractionated radiotherapy after 
conventional EBRT is feasible with acceptable risk of toxicity 
in pts with relapsed prostate cancer. Initial data suggest 
effectivness of this approach but a longer follow up and a 
larger number of pts are needed to confirm it. 
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Purpose/Objective: A number of studies have been 
published, which predict the probability of acute and late 
toxicity after radiotherapy (RT) for prostate cancer (Pca), but 
no user-friendly tool is available to help radiation oncologists 
applying the results coming from these studies. Aim of this 
work was therefore to design and build a web application 
which can support radiation oncologists in treatment planning 
and evaluation, by computing the probabilities of various 
acute and long term toxicities, as a function of dose 
distribution to organs at risk and patient's characteristics. 
Materials and Methods: 4 published studies devoted to 
prediction of acute and late GI toxicity after RT for Pca and 
presenting predictive models based on logistic regression 
were considered. Current web and database technologies 
were used to develop the web tool by means of open source 
software (HTML, PHP, Javascript, MySQL). 11 models (5 for 
acute and 6 for late toxicity) have been configured into the 
system and new models could possibly be added in the 
future. Model and variable names, with their regression 
coefficients and their standard errors when available, are 
stored in a database and used to compute in real-time the 
probabilities of the different endpoints. We chose to insert a 
free registration procedure before use of the web tool is 
allowed, in order to have a check on people accessing it. The 
web application can be used by any of the most common 
browsers (Chrome, Mozilla Firefox, Internet Explorer). 
Results: The user can chose between models including the 
actual dose distribution in the patient, if a RT plan is already 
available, or models giving probabilities for different 
standard dose-volume levels. Probability uncertainties are 
